L-ASPARAGINASA EFECTOS ADVERSOS PDF
Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.
|Published (Last):||12 October 2015|
|PDF File Size:||19.88 Mb|
|ePub File Size:||14.61 Mb|
|Price:||Free* [*Free Regsitration Required]|
Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible. Trials with results Trials without results.
IMP with orphan designation in the indication. Subjects are under 18 years old.
l-asparaginasa efectos adversos pdf – PDF Files
Active treatment for graft-versus-host disease 6. Karnofsky or Lansky scores? Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute l-awparaginasa leukemia ALL -To determine the l-asparaginaas tolerated dose MTD of carfilzomib in combination with induction chemotherapy.
Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Committee on Advanced therapies CAT has issued a classification for this product.
Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment. Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy?
Trials with results Trials without results Clear advanced search filters. Adequate liver function, defined as both of the following: Age 18 years or younger at the time of study treatment initiation.
Title of the trial for lay people, in easily understood, i. EU Clinical Trials Register. Date on which this record was first entered in the EudraCT database:. Pneumonia AND sponsor name. Review by the Competent Authority or Ethics Committee in the country concerned. Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition.
Medicinas para Quimioterapia – Nombres de Medicina
Combination product that includes a device, but does not involve an Advanced Therapy. The duration of this interval must be approved by l-qsparaginasa Onyx study medical monitor.
Known allergy to any of the drugs used in the study. Cancer AND drug name.
L-asoaraginasa allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc. Restricciones de tratamientos previos: Positive culture for bacteria or fungus within 14 days of the initiation of therapy 7. Both Female Only Male Only. Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p. The trial involves single site in the Member State concerned.
For these items you should use the filters and not add them to your search terms in the text field. Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial. A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells. Relapsed or Refractory Acute Lymphoblastic Leukemia. Clear advanced search filters. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
Subjects must have a serum creatinine level that is?
How to search [pdf]. Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia. The IMP has been designated in this indication as an orphan l-asparabinasa in the Community.